Life Healthcare's 1H26 results met guidance with 2.4% revenue growth and 8.4% NEPS growth. Goldman Sachs maintains its Neutral rating and R13.20 price target.
Key Takeaways
- 1.Life Healthcare's 1H26 results were in line with the previously issued trading statement, with revenue growing 2.4% yoy to R12.4bn.
- 2.Management's FY26 strategy focuses on capacity expansion, including adding 87 acute hospital beds and growing the diagnostics business with 3 new PET-CT sites.
- 3.Goldman Sachs maintains a Neutral rating with a 12-month price target of R13.20, valuing the company using an EV/EBITDA methodology.
Table of Contents
- Outlook for FY26
- Disclosure Appendix
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Company-specific regulatory disclosures
- Distribution of ratings/investment banking relationships
- Price target and rating history chart(s)
- Target price history table(s)
- Regulatory disclosures
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Harsh MehtaVaishnavi Gupta
Securities
LHCJ.JNetcare Ltd.
Themes
Healthcare capacity expansionRegulatory risk and NHI ActDiagnostic business growth
Regions
AfricaSouth Africa